Literature DB >> 9000641

Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats.

K Sugimoto1, K Sakamoto, A Fujimura.   

Abstract

To assess the pharmacokinetic interaction of cyclosporin A with probucol, we administered cyclosporin A (10 mg/kg body weight) to rats orally or intravenously with or without pretreatment of probucol (10 mg/animal, daily for 8 days). The whole blood cyclosporin A concentration-time curves after oral administration showed a 34% reduction in peak concentration and a 30% decrease in area under the blood concentration-time curve (AUC) by administration of probucol. No apparent change in elimination half-life or volume of the central compartment was observed with the treatment of probucol. After intravenous administration of cyclosporin A, the blood levels could be described by a two-compartment open model. No differences were observed in the AUC, elimination half-life or total clearance of cyclosporin A by the pretreatment of probucol. Calculated bioavailability following oral administration of cyclosporin A decreased by 33% with the treatment of probucol. These results suggest that probucol may not profoundly influence the disposition of cyclosporin A. Coadministration of probucol could decrease the fraction of absorbed cyclosporin A after oral administration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000641     DOI: 10.1016/s0024-3205(96)00613-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats.

Authors:  Mari Jiko; Ikuko Yano; Hiroko Wakasugi; Hideyuki Saito; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

Review 2.  Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.

Authors:  Anders Asberg
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.